Market News
5 min read | Updated on December 17, 2024, 13:16 IST
SUMMARY
Shares of ITC were trading more than 0.6% higher at ₹473 apiece on the BSE after the company announced it had set the demerger date for its hotel business as January 1, 2025.
Stock list
At around 12:30 PM, the S&P BSE SENSEX was trading at 80,983.84, down 765 points, or 0.94%
At around 12:30 PM, the S&P BSE SENSEX was trading at 80,983.84, down 765 points, or 0.94%, while the NIFTY50 index was trading at 24,436.50, down 232 points, or 0.94%.
The fourth interim dividend will be paid to shareholders whose names appear on the company's register as of the record date of December 24, 2024, the company said.
It has been a listless year for the oil-to-telecom conglomerate as weak financial results weighed on the sentiment.
In an exchange filing on Monday, HDFC Bank informed that SEBI issued an administrative warning letter to the bank alleging non-compliance with the market regulator's listing regulations regarding the resignation of Arvind Kapil, the head of the bank's mortgage business.
The market regulator advised the bank to exercise due caution in the future and avoid the recurrence of such instances. "Failing which appropriate enforcement action may be initiated," it added.
The private lender reported a 4% surge in its profit after tax (PAT) to ₹138.4 crore for the second quarter of the financial year 2024-25. In the year-ago period, CSB Bank posted a net profit of ₹133.2 crore.
The pharma company reported over a four-fold increase in consolidated net profit at ₹23 crore for the second quarter that ended in September.
The Mumbai-based company had reported a net profit of ₹5 crore in the July-September quarter of last fiscal.
Revenue from operations rose to ₹2,242 crore in the second quarter as compared with ₹1,911 crore in the year-ago period.
The opening date of the issue was Monday, December 16.
Further, the floor price for the issue is set at ₹2,616.55 per equity share, based on the pricing formula.
Earlier, in the morning, the pharma company announced the signing of a binding Letter of Intent (LOI) with the University of California, San Francisco (UCSF), through the office of OTMA, and Tiller Therapeutics Inc. (Tiller) to license SPARC’s rights in the joint intellectual property (IP) held between SPARC and UCSF for a pre-clinical oncology asset along with associated IP.
The LOI outlines the key terms of the license and rights for development and commercialisation by Tiller.
About The Author
Next Story